FDA approves Pharmacia's Bextra

The FDA granted marketing approval to PHA and partner Pfizer (PFE) for Bextra valdecoxib, a once-daily COX-2 inhibitor to treat osteoarthritis (OA) and adult rheumatoid arthritis (RA), and as a twice daily treatment for pain associated with menstrual cramps. PHA and PFE already market Celebrex celecoxib to treat OA, RA and familial adenomatous polyposis. ...